

Using Growth Charts in Alagille Syndrome

Written by The Life Science Feed Editorial Team · Published 28 September 2026 · Edited by Mara Voss

Alagille Syndrome (ALGS) is a rare genetic disorder that significantly impacts growth due to chronic cholestasis and associated nutritional deficiencies. Standard growth charts, designed for typically developing children, often underestimate growth deficits in children with ALGS, potentially delaying crucial nutritional interventions. Condition-specific growth charts for ALGS offer a more accurate tool for monitoring growth and guiding timely support.

KEY TAKEAWAYS

- **The Pivot:** Standard growth charts are inadequate for children with Alagille Syndrome (ALGS) due to their unique nutritional and metabolic challenges, necessitating the use of ALGS-specific growth charts for accurate assessment.
- **The Data:** Children with ALGS commonly experience failure to thrive, short stature, and delayed puberty, with their growth patterns deviating substantially from typically developing children.
- **The Action:** Integrate ALGS-specific growth charts into your practice to enable earlier identification of growth deficits and malnutrition, facilitating timely and tailored nutritional interventions in children with ALGS.

Alagille Syndrome and Growth

Alagille Syndrome (ALGS) is a rare genetic disorder affecting multiple organ systems, most notably the liver, heart, eyes, and skeleton.^{3,4} Cholestasis, or impaired bile flow, is a hallmark of the condition and contributes significantly to nutritional deficiencies.³ These deficiencies, in turn, directly impact growth.³ Children with ALGS often experience failure to thrive, short stature, and delayed puberty.^{3,4} Their growth patterns deviate substantially from those of healthy children, making the interpretation of standard growth charts problematic.^{1,2}

Limitations of Standard Charts

The Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) growth charts are designed for typically developing children.¹ They do not account for the specific nutritional challenges and metabolic abnormalities associated with ALGS. Using these standard charts for children with ALGS can lead to underestimation of growth deficits and delayed intervention. For example, a child with ALGS whose weight is at the 10th percentile on a standard chart might actually be severely malnourished when compared to their ALGS peers. Relying solely on standard charts could delay referral to a gastroenterologist or nutritionist, delaying crucial interventions.

This approach contradicts expert guidelines for managing cholestatic liver disease in children, which emphasize the need for early and aggressive nutritional support. The North American Society for Pediatric Gastroenterology, Hepatology

and Nutrition (NASPGHAN) recommends a proactive approach to identify and address nutritional deficiencies in children with chronic liver disease. Standard growth charts simply are not sensitive enough to detect subtle, yet clinically significant, deviations from the ALGS-specific growth trajectory.

Condition-Specific Growth Charts

Condition-specific growth charts for ALGS offer a more accurate and relevant tool for monitoring growth in these children.^{1,2} These charts are developed using data collected from a cohort of children diagnosed with ALGS, reflecting their unique growth patterns.¹ By using ALGS-specific charts, clinicians can more accurately assess a child's growth status, identify malnutrition earlier, and tailor nutritional interventions accordingly. These charts typically present data as z-scores, allowing clinicians to easily compare a child's measurements to the ALGS population mean.

The key advantage here is precision. Instead of comparing an apple to an orange, we're comparing apples to apples. This enables clinicians to have more informed and productive conversations with parents. Instead of vaguely saying, "Your child is a little small," we can say, "Compared to other children with Alagille Syndrome, your child's weight is in the Xth percentile, which indicates a need for increased caloric intake and closer monitoring." It transforms the conversation from a point of anxiety to a point of actionable steps.

Study Limitations

While the concept of condition-specific growth charts is appealing, it's important to acknowledge the limitations of the data underpinning them.^{1,2} Many of these charts are based on relatively small sample sizes, reflecting the rarity of ALGS. The generalizability of these charts to diverse populations may also be limited. Furthermore, the methodology used to construct these charts can vary, making it difficult to compare results across different studies.¹ We must ask: Is this data truly reproducible across centers, or is it heavily influenced by the specific patient population at the originating institution?

Integrating the Charts into Practice

So, how do we actually use these charts in our day-to-day practice? First, ensure that the ALGS-specific growth chart is readily available in your clinic's electronic health record (EHR) system. Second, train all staff members, including nurses and medical assistants, on how to use the chart and interpret the results. Third, use the chart as a visual aid during consultations with parents. Show them how their child's growth compares to other children with ALGS. Explain the implications of the growth pattern and outline the steps you will take to address any concerns.

Beyond simply plotting data, consider how the chart informs your overall management strategy. Does it trigger a more in-depth nutritional assessment? Does it prompt referral to a specialist? Does it necessitate more frequent monitoring? The chart is not just a piece of paper; it's a decision-support tool that can help you provide the best possible care for your patients with Alagille Syndrome.

CLINICAL IMPLICATIONS

The most striking consequence of relying on standard growth charts for Alagille Syndrome (ALGS) is the potential for delayed intervention. This delay can have significant long-term health implications for children

with ALGS. General practitioners and specialists must understand that standard CDC or WHO charts are simply inadequate. This approach directly contradicts expert guidelines from bodies like NASPGHAN, which advocate for proactive nutritional support in pediatric cholestatic liver disease.

Industry has a clear role here. Pharmaceutical companies developing therapies for ALGS, or even nutritional product manufacturers, should support the widespread adoption and integration of ALGS-specific growth charts into electronic health record (EHR) systems across Europe. This is not just about patient care; it's about accurate monitoring of treatment efficacy in real-world settings. Without precise tools, the benefits of innovative therapies might be underestimated.

For patients and their families, these condition-specific charts offer clarity and empowerment. They transform vague concerns into actionable insights, fostering more productive conversations with clinicians. While the evidence base for some of these charts is still developing due to small sample sizes, their clinical utility in guiding nutritional support and identifying early signs of malnutrition is undeniable. We must embrace these tools, even as we advocate for more robust data collection.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. Huysentruyt K, Vandriel SM, Roelants M, et al. Condition-Specific Growth Charts for Children With Alagille Syndrome. JAMA Netw Open. 2025;8(11):e2545294. doi:10.1001/jamanetworkopen.2025.45294
2. Zemel BS. Influence of complex childhood diseases on variation in growth and skeletal development. Am J Hum Biol. 2017;29(2). doi:10.1002/ajhb.22985
3. Maharjana MA, Suyasa IK, Kawiya IKS, Nugraha HK. Pathological fracture of the femur in Alagille Syndrome: A case report. J Clin Orthop Trauma. 2020;11(2):298-301. doi:10.1016/j.jcot.2019.12.009
4. Polemikos M, Hermann EJ, Heissler HE, Hartmann H, Krauss JK. Pseudotumor cerebri syndrome in a child with Alagille syndrome: intracranial pressure dynamics and treatment outcome after ventriculoperitoneal shunting. Childs Nerv Syst. 2021;37(9):2899-2904. doi:10.1007/s00381-021-05043-9

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

thelifesciencefeed.com

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed